Search Results - "Goswami, Trishna"

637 INB-200: Phase I study of gene modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM) patients receiving maintenance temozolomide (TMZ): immunobiologic correlative data by Lamb, Lawrence, Lobbous, Mina, Goswami, Trishna, Rochlin, Kate, Shepard, Joy, Weekley, Becca B, Lucas, Caitlyn, Langford, Cathy, Youngblood, Samantha, Haak, Mariska Ter, Burt Nabors, L

“…BackgroundDrug Resistant Immunotherapy (DRI) combines an alkylating chemotherapy such as temozolomide (TMZ) to force the upregulation of tumor…”
Get full text

CTIM-35. INB-400 PHASE 1B/2 DRUG RESISTANT IMMUNOTHERAPY WITH ACTIVATED, GENE MODIFIED ALLOGENEIC OR AUTOLOGOUS ΓΔ T CELLS IN COMBINATION WITH MAINTENANCE TEMOZOLOMIDE RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA by Goswami, Trishna, Lamb, Lawrence, Rochlin, Kate, Nabors, Burt

“…Abstract Gamma delta (gd) T cells are innate immune cells that synergistically target cancer cells via NKG2D ligands (NKG2D-L) upregulated by chemotherapy…”
Get full text

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors by Tagawa, Scott T, Balar, Arjun V, Petrylak, Daniel P, Kalebasty, Arash Rezazadeh, Loriot, Yohann, Fléchon, Aude, Jain, Rohit K, Agarwal, Neeraj, Bupathi, Manojkumar, Barthelemy, Philippe, Beuzeboc, Philippe, Palmbos, Phillip, Kyriakopoulos, Christos E, Pouessel, Damien, Sternberg, Cora N, Hong, Quan, Goswami, Trishna, Itri, Loretta M, Grivas, Petros

“…Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited…”
Get full text

CTIM-09. INB-200: FULLY ENROLLED PHASE 1 STUDY OF GENE-MODIFIED AUTOLOGOUS GAMMA-DELTA (ΓΔ) T CELLS IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS RECEIVING MAINTENANCE TEMOZOLOMIDE (TMZ) by Lobbous, Mina, Goswami, Trishna, Lamb, Larry, Rochlin, Kate, Pillay, Thiru, ter Haak, Mariska, Nabors, Louis B

“…Abstract IN8bio’s DeltEx drug resistant immunotherapy (DRI), comprising TMZ-resistant γδ T cells engineered to express methylguanine-DNA methyltransferase…”
Get full text

Inb-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy) by McGuirk, Joseph P, Abhyankar, Sunil, Goswami, Trishna, Juarez, Halie, ter Haak, Mariska, Bruns, Tyce, Youngblood, Samantha, Lamb, Lawrence S.

“…Background: Gamma-delta (gd) T cells are MHC unrestricted lymphocytes that recognize and lyse malignant cells in allogeneic settings. Although haploidentical…”
Get full text

INB-200 phase I study of gene modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ) by Lobbous, Mina, Goswami, Trishna, Lamb, Lawrence S., Rochlin, Kate, Pillay, Thriumaine, Youngblood, Samantha, ter Haak, Mariska, Nabors, Louis B.

“…2007 Background: MHC unrestricted γδ T cells target NKG2D ligands upregulated on tumor cells. IN8bio’s DeltEx chemotherapy resistant cell therapy (CRCT), is a…”
Get full text

Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ) by Nabors, Louis B., Lobbous, Mina, Lamb, Lawrence S., Rochlin, Kate, Pillay, Thriumaine, Youngblood, Samantha, ter Haak, Mariska, Goswami, Trishna

“…2044 Background: γδ T cells, MHC unrestricted immune cells, target NKG2D ligands differentially expressed on tumor cells. DeltEx drug resistant immunotherapy…”
Get full text

CTIM-42. INB-200: PHASE 1 STUDY OF GENE MODIFIED AUTOLOGOUS GAMMA-DELTA (ΓΔ) T CELLS IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS RECEIVING MAINTENANCE TEMOZOLOMIDE (TMZ) by Lobbous, Mina, Goswami, Trishna, Lamb, Lawrence, Rochlin, Kate, Pillay, Thiumaine, Youngblood, Samantha, ter Haak, Mariska, Nabors, Burt

“…Abstract γδ T cells target NKG2D ligands that are upregulated on tumor cells after chemotherapy exposure. IN8bio’s DeltEx drug resistant immunotherapy (DRI)…”
Get full text

Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial by McGuirk, Joseph P., Abhyankar, Sunil H, Goswami, Trishna, Soder, Rupal, ter Haak, Mariska, Bruns, Tyce, Youngblood, Samantha Langford, Lamb, Lawrence S.

Get full text

TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC) by Tagawa, Scott T., Grivas, Petros, Petrylak, Daniel P., Sternberg, Cora N., Swami, Umang, Bhatia, Astha, Pichardo, Cabilia, Goswami, Trishna, Loriot, Yohann

“…Abstract only TPS581 Background: Cis-based combination chemotherapy regimens with gemcitabine or methotrexate, vinblastine, and doxorubicin are commonly used…”
Get full text

TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors by Saxena, Ashish, Michel, Loren S., Hong, Quan, Hilsinger, Karrie, Kanwal, Charu, Pichardo, Cabilia, Goswami, Trishna, Santin, Alessandro

“…Abstract only TPS3648 Background: Trophoblast cell surface antigen (Trop-2) is highly expressed in many epithelial cancers (non–small-cell lung cancer [NSCLC],…”
Get full text

Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study by Santin, Alessandro, Komiya, Takefumi, Goldenberg, David M., Sharkey, Robert M., Hong, Quan, Wegener, William A., Goswami, Trishna, Bardia, Aditya

“…Abstract only 6081 Background: Unselected pts with EC who progressed on prior chemotherapy have a poor prognosis with limited treatment options. SG is a novel…”
Get full text

TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy by Vulsteke, Christof, Grivas, Petros, Tagawa, Scott T., Bellmunt, Joaquim, De Santis, Maria, Duran, Ignacio, Goebell, Peter-Juergen, Necchi, Andrea, Sridhar, Srikala S., Sternberg, Cora N., Sierecki, Mitchell Robert, Aziz, Usman, Goswami, Trishna, Loriot, Yohann

“…Abstract only TPS582 Background: Treatment options are limited for pts with LA unresectable or mUC who progress after prior PLT-based and CPI therapies. SG is…”
Get full text

TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens by Grivas, Petros, Pouessel, Damien, Park, Chandler H., Barthélémy, Philippe, Bupathi, Manojkumar, Petrylak, Daniel P., Agarwal, Neeraj, Flechon, Aude, Ramamurthy, Chethan, Davis, Nancy B., Recio-Boiles, Alejandro, Tagawa, Scott T., Sternberg, Cora N., Bhatia, Astha, Pichardo, Cabilia, Goswami, Trishna, Loriot, Yohann

“…Abstract only 434 Background: Checkpoint inhibitors (CPIs) are standard therapy for pts with mUC after PLT-based regimens, with limited long-term disease…”
Get full text

TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy by Tagawa, Scott T., Petrylak, Daniel Peter, Grivas, Petros, Agarwal, Neeraj, Sternberg, Cora N., Hernandez, Chris, Siemon-Hryczyk, Peggy, Goswami, Trishna, Loriot, Yohann

“…Abstract only TPS3153 Background: Patients (pts) with advanced urothelial cancer (UC) who progress after checkpoint inhibitor (CPI) therapy (following failure…”
Get full text

Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy by Petrylak, Daniel Peter, Tagawa, Scott T., Jain, Rohit K., Bupathi, Manojkumar, Balar, Arjun Vasant, Rezazadeh, Arash, George, Saby, Palmbos, Phillip Lee, Nordquist, Luke T., Davis, Nancy B., Vogelzang, Nicholas J., Ramamurthy, Chethan, Sternberg, Cora N., Loriot, Yohann, Agarwal, Neeraj, Hong, Quan, Gladden, Allison, Kanwal, Charu, Goswami, Trishna, Grivas, Petros

“…Abstract only 5027 Background: SG is an antibody-drug conjugate consisting of a humanized monoclonal anti–Trop-2 antibody coupled to the cytotoxic agent,…”
Get full text

A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530) by Zandberg, Dan Paul, Jarkowski, Anthony, Emeribe, Ugochi A, Goswami, Trishna, Melillo, Giovanni

“…Abstract only…”
Get full text

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis by Patnaik, Mrinal M., Gupta, Vikas, Schiller, Gary J., Lee, Sangmin, Yacoub, Abdulraheem, Ali, Haris, Talpaz, Moshe, Sardone, Megan, Wysowskyj, Halyna, Shemesh, Shay, Chen, Janice, Brooks, Christopher, Goswami, Trishna, Pardanani, Animesh, Tefferi, Ayalew, Verstovsek, Srdan, Khoury, Joseph David, Pemmaraju, Naveen

“…Background: SL-401 is a novel targeted therapy, comprised of recombinant IL-3 genetically fused to a truncated diphtheria toxin payload, directed to the…”
Get full text

Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival by Peereboom, David M., Nabors, Louis B., Kumthekar, Priya, Badruddoja, Michael A., Fink, Karen L., Lieberman, Frank S., Phuphanich, Surasak, Dunbar, Erin M., Walbert, Tobias, Schiff, David, Tran, David Dinh, Ashby, Lynn Stuart, Butowski, Nicholas A., Iwamoto, Fabio Massaiti, Lindsay, Ross, Bullington, John, Schulder, Michael, Sherman, Jonathan, Goswami, Trishna, Reardon, David A.

“…Abstract only…”
Get full text

Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL) by Ravandi, Farhad, Kantarjian, Hagop M., Goswami, Trishna, Wang, Fujun, Ibrahim, Ramy

“…Adult ALL encompasses a heterogeneous group of lymphoid malignancies. Long-term survival in adults is currently only 35% to 45%; the predominant reason for…”
Get full text